Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Adimab LLC operates in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 2 pending office actions. These actions are being handled by 2 distinct examiners, but they are both within 1 distinct art unit, indicating that the technology remains concentrated within a specialized group at the USPTO. This suggests that while different individuals are reviewing the applications, the technical focus remains narrow.
The busiest examiner for the portfolio is EDGINGTONGIORDANO, FRANCESCA, who is managing 1 busiest examiner pending action. This accounts for a portion of the 2 pending office actions currently active. The fact that 2 distinct examiners are working within 1 distinct art unit indicates a specific technical focus for the company's current filings. For practitioners, this requires managing consistent arguments across different examiners who are operating under the same art unit standards.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EDGINGTONGIORDANO, FRANCESCA | 1 | 71.8% | +29.4% |
| VAN DRUFF, SYDNEY | 1 | 55.3% | +32.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18692097 | ANTI-CD3 ANTIBODIES | EDGINGTONGIORDANO, FRANCESCA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18692097 | ANTI-CD3 ANTIBODIES | EDGINGTONGIORDANO, FRANCESCA | — |
| 18682205 | ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND USES THEREOF | VAN DRUFF, SYDNEY | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18692097 | ANTI-CD3 ANTIBODIES | EDGINGTONGIORDANO, FRANCESCA | 1643 | §102§112Other | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18682205 | ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND USES THEREOF | VAN DRUFF, SYDNEY | 1643 | §102§112DP | Non-Final OA | — | Pending | Feb 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAdimab LLC has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Francesca Edgingtongiordano has the most, with 1 of Adimab LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
